Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
10.33
-0.09 (-0.86%)
At close: Aug 1, 2025, 4:00 PM
10.17
-0.16 (-1.55%)
After-hours: Aug 1, 2025, 7:37 PM EDT

Company Description

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions.

The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.

It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device.

Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics logo
CountryUnited States
Founded2022
IPO DateJan 20, 2023
IndustryBiotechnology
SectorHealthcare
Employees4
CEOQuang Pham

Contact Details

Address:
822 A1A North, Suite 306
Ponte Vedra, Florida 32082
United States
Phone904 300 0701
Websitecadrenal.com

Stock Details

Ticker SymbolCVKD
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$5.00
CIK Code0001937993
ISIN NumberUS1276362076
Employer ID88-0860746
SIC Code2834

Key Executives

NamePosition
Quang X. PhamChairman and Chief Executive Officer
Matthew K. Szot CPA, CPACo-Founder and Chief Financial Officer
Jeffrey ColeChief Operating Officer
Dr. James J. Ferguson FACC, M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jul 31, 2025ARSFiling
Jul 31, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 31, 2025DEF 14AOther definitive proxy statements
Jul 18, 20258-KCurrent Report
May 8, 20258-KCurrent Report
May 8, 202510-QQuarterly Report
Apr 17, 20258-KCurrent Report
Apr 17, 2025424B5Filing
Mar 13, 20258-KCurrent Report
Mar 13, 202510-KAnnual Report